Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$471 Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$-- Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
5.7
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
0
Div. Yield
11.3 %
Debt to Equity
--
Book Value
$17.8
EPS
$3
Face value
--
Shares outstanding
29,598,692
CFO
$-52.57 Mln
EBITDA
$484.77 Mln
Net Profit
$249.93 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
TeklaLife Sciences Investors (HQL)
| 0.4 | 1.2 | 0.4 | 32.8 | 6.5 | -3.1 | -0.6 |
|
BSE Sensex*
| -13.8 | -10.2 | -14.3 | -4.0 | 7.3 | 7.8 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
TeklaLife Sciences Investors (HQL)
| 27.9 | -2.5 | -5.3 | -26.1 | -2.6 | 13.3 | 15.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
TeklaLife Sciences Investors (HQL)
|
16.9 | 470.9 | 86.4 | 85.6 | -- | 17.6 | 5.7 | 0.9 |
| 14.4 | 1,453.2 | 225.0 | 222.0 | -- | 13.4 | 6.5 | 0.9 | |
| 22.6 | 1,458.1 | 266.0 | 314.4 | -- | 20.3 | 4.6 | 0.9 | |
| 10.1 | 2,786.7 | 1,171.0 | 11.0 | 56.7 | 0.2 | 248.8 | 0.5 | |
| 59.3 | 1,368.4 | 163.9 | 339.8 | 27.3 | 20.6 | 3.9 | 0.9 | |
| 13.8 | 2,418.5 | -42.2 | -46.9 | 60.8 | -1.9 | -- | 1.0 | |
| 13.1 | 972.7 | 325.8 | 321.3 | -- | 25.6 | 3 | 0.7 | |
| 2.6 | 1,221.1 | -64.3 | -234.2 | 159.9 | -7.9 | -- | 0.4 | |
| 17.3 | 1,611.5 | 101.9 | 174.1 | -- | 8 | 9.3 | 0.7 | |
| 32.0 | 1,654.2 | 204.6 | 254.3 | -- | 13.1 | 6.3 | 0.9 |
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector,... including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Address: 1900 Market Street, Philadelphia, PA, United States, 19103 Read more
Principal Executive Officer, President and Trustee
Dr. Daniel R. Omstead M.S, Ph.D.
Principal Executive Officer, President and Trustee
Dr. Daniel R. Omstead M.S, Ph.D.
Headquarters
Philadelphia, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of TeklaLife Sciences Investors (HQL) is $16.85 (NYSE) as of 01-Apr-2026 16:00 EDT. TeklaLife Sciences Investors (HQL) has given a return of 6.55% in the last 3 years.
The P/E ratio of TeklaLife Sciences Investors (HQL) is 5.70 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
5.23
|
0.87
|
|
2024
|
5.09
|
0.94
|
|
2023
|
14.95
|
0.83
|
|
2022
|
-3.35
|
0.88
|
|
2021
|
7.95
|
0.98
|
The 52-week high and low of TeklaLife Sciences Investors (HQL) are Rs 17.80 and Rs 10.55 as of 02-Apr-2026.
TeklaLife Sciences Investors (HQL) has a market capitalisation of $ 471 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in TeklaLife Sciences Investors (HQL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.58
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.